<DOC>
	<DOCNO>NCT00203190</DOCNO>
	<brief_summary>Topiramate medication approve Food Drug Administration ( FDA ) treatment patient seizure . The trade name drug TopamaxÂ® . Topiramate approve FDA treatment cluster headache experimental purpose research study . If subject participates study , he/she increase his/her dose topiramate rapidly first week try stop cluster attack continue maintenance dose topiramate order determine prevent attack occur cluster period . We believe lead faster complete remission cluster period .</brief_summary>
	<brief_title>A Double-Blind , Placebo-Controlled Study Examining Use Topiramate Treatment Cluster Headache</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Cluster Headache</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Subjects age 18 65 diagnosis cluster headache ( episodic chronic ) define International Classification Headache Disorders ( 2nd edition ) Subjects must lifetime prevalence least 2 prior cluster cycle . Subjects must experience one attacks/ day baseline period Subjects must typical cluster period last least 8 week . Subjects must present active cluster period expect remain duration cluster cycle must least 8 week Baseline visit . Subjects headache type eligible provide subject able differentiate headache cluster headache . Subject use agrees use duration participation medically acceptable form contraception ( determined investigator ) , female childbearing potential Subject negative urine pregnancy test prior study entry , female childbearing potential Subject able understand comply study requirement Subject provide write informed consent prior screen procedure conduct Women pregnant lactating Subjects , investigator opinion , history evidence medical psychiatric condition would expose increase risk significant adverse event would interfere assessment efficacy tolerability trial Subjects require change medication exist regimen medication prophylaxis cluster 4 week prior Baseline visit duration trial Subjects cluster headache typically exceed 4 hour Subjects use follow medications/ treatment four week prior Baseline visit : corticosteroid nerve block . Subjects use drug might interact adversely , interfere action , study medication ( e.g. , carbonic anhydrase inhibitor ) Subjects failed adequate trial topiramate cluster headache due lack efficacy adverse event , determine investigator Subjects history nephrolithiasis . Subjects allergic show hypersensitivity topiramate agent similar topiramate Subjects abuse opioids determine investigator Subjects history significant drug alcohol abuse within past year Subjects participate investigational drug trial 30 day prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>